- Home
- GPRK vs AKBA Comparison
GPRK vs AKBA Comparison
Compare GPRK & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRK
- AKBA
- Stock Information
- Founded
- GPRK 2002
- AKBA 2007
- Country
- GPRK Colombia
- AKBA United States
- Employees
- GPRK N/A
- AKBA N/A
- Industry
- GPRK Oil & Gas Production
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- GPRK Energy
- AKBA Health Care
- Exchange
- GPRK Nasdaq
- AKBA Nasdaq
- Market Cap
- GPRK 324.3M
- AKBA 336.2M
- IPO Year
- GPRK N/A
- AKBA 2014
- Fundamental
- Price
- GPRK $6.54
- AKBA $2.14
- Analyst Decision
- GPRK Buy
- AKBA Strong Buy
- Analyst Count
- GPRK 1
- AKBA 3
- Target Price
- GPRK $11.00
- AKBA $6.50
- AVG Volume (30 Days)
- GPRK 895.9K
- AKBA 4.5M
- Earning Date
- GPRK 05-14-2025
- AKBA 05-08-2025
- Dividend Yield
- GPRK 9.01%
- AKBA N/A
- EPS Growth
- GPRK N/A
- AKBA N/A
- EPS
- GPRK 1.81
- AKBA N/A
- Revenue
- GPRK $660,838,000.00
- AKBA $160,180,000.00
- Revenue This Year
- GPRK N/A
- AKBA $22.50
- Revenue Next Year
- GPRK $10.05
- AKBA $43.23
- P/E Ratio
- GPRK $3.49
- AKBA N/A
- Revenue Growth
- GPRK N/A
- AKBA N/A
- 52 Week Low
- GPRK $5.66
- AKBA $0.80
- 52 Week High
- GPRK $11.72
- AKBA $2.89
- Technical
- Relative Strength Index (RSI)
- GPRK 41.76
- AKBA 59.49
- Support Level
- GPRK $6.26
- AKBA $1.52
- Resistance Level
- GPRK $6.76
- AKBA $2.16
- Average True Range (ATR)
- GPRK 0.47
- AKBA 0.15
- MACD
- GPRK 0.01
- AKBA 0.04
- Stochastic Oscillator
- GPRK 36.36
- AKBA 96.88
About GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil and Argentina. The company generates revenue from the sale of crude oil, condensate and natural gas net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.